Surrogate Measures of Drug Efficacy—A Finger Pointing at the Moon

The author criticizes the widespread reliance on surrogate endpoints to approve cancer drugs, noting that many such approvals fail to translate into real survival benefits. Stronger post‑approval reassessment and conditional approval frameworks are needed to prioritize meaningful clinical outcomes over early but unreliable signals.